ESTRO 2024 - Abstract Book

S5095

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2024

5. Detsky, J. S. et al. Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology. J. Neurooncol. 134, 433–441 (2017). 6. Telera, S. et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J. Neurooncol. 113, 313–325 (2013). 7. Truong, M. T. et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery 59, 86–97; discussion 86-97 (2006). 8. Vellayappan, B. et al. Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Front. Oncol. 8, 395 (2018). 1975

Digital Poster

Validating MR Hypoxia Detection in Prostate Cancer using pimonidazole and GLUT1

Martin Swinton 1,2 , Michael Dubec 3,2 , Damien McHugh 3,2 , Ashwin Sachdeva 4,2 , Christopher Moore 3,2 , Emma Biglin 2 , Diego F Sanchez 5 , Pedro Oliveira 5 , Claire A Hart 2 , Vijay Ramani 4 , Maurice Lau 4 , Jeremy Oates 4 , Noel Clarke 4 , Gareth Price 2 , Alan McWilliam 2 , Marcel van Herk 2 , Peter Hoskin 2 , David Buckley 6 , Andrew Hudson 1 , Ananya Choudhury 1,2 , Robert Bristow 2 1 The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom. 2 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 3 The Christie NHS Foundation Trust, Medical Physics and Engineering, Manchester, United Kingdom. 4 The Christie NHS Foundation Trust, Department of Surgery, Manchester, United Kingdom. 5 The Christie NHS Foundation Trust, Histopathology, Manchester, United Kingdom. 6 University of Leeds, Medical Physics, Leeds, United Kingdom

Purpose/Objective:

Intra-tumoral hypoxia in prostate cancer (PCa) is associated with worse prognosis after radical treatment. [1,2] MR detection of hypoxia could identify men who benefit from hypoxia-modification or treatment intensification. Doing this on a magnetic resonance linear accelerator (MRL) system would allow dynamic measurement of hypoxia during radiotherapy. The aims of this study were (1) to develop a protocol for quantitative hypoxia-sensitive MRI (2) to validate this protocol in prostate cancer (PCa) against pimonidazole and GLUT1 stained prostatectomy sections.

Material/Methods:

The Hyprogen trial (NCT05702619) investigates novel MR imaging of tumour hypoxia prior to radical prostatectomy. The MR hypoxia detection protocol was developed on a diagnostic 1.5 T MR and 1.5 T MRL with healthy volunteers and PCa patients. Sequence time was 50-55 minutes and includes Blood oxygen level-dependent (BOLD), intravoxel incoherent motion (IVIM), oxygen-enhanced (OE) and dynamic contrast-enhanced (DCE) MRI sequences; methods hypothesised to detect hypoxic sub-regions. Imaging was acquired twice prior to surgery to allow evaluation of within scanner repeatability and between scanner-reproducibility.